NEJM data support Takeda’s treatment for ITP
The New England Journal of Medicine (NEJM) has published final results from a Phase II study evaluating Takeda’s mezagitamab (TAK-079), an investigational treatment option for patients with primary immune thrombocytopenia (ITP).
The NEJM-published data showed patients treated with mezagitamab achieved:
- Rapid platelet response as early as Day 2 with median time to first platelet response of four days, defined as platelet count ³50,000/uL and ³20,000/uL above baseline.
- Durable platelet response that persisted through Week 24, defined as platelet counts ³50,000/uL for ³4 of the last six visits between Weeks 10 and 24.
- Dose-dependent efficacy with the highest platelet response observed at the 600mg dose (90.9% with mezagitamab 600mg vs. 23.1% with placebo).
- Improved health-related quality of life scores through Week 16 compared to placebo.
- Comparable safety profile with a similar incidence of adverse events between mezagitamab and placebo groups.
A global Phase III trial of mezagitamab in ITP is currently underway with anticipated completion in 2027.
ITP is a rare immune-mediated bleeding disorder characterised by the accelerated destruction and impaired production of platelets. This results in decreased platelet counts and increased risk of bleeding, which can cause fatigue, impair quality of life, and in severe cases, may be life-threatening.
David Kuter, Director of Clinical Hematology at Massachusetts General Hospital and principal investigator of the study, said: “Patients with ITP face significant disease burden with roughly 20% of patients not achieving recommended platelet levels following treatment with first- and second-line options. These Phase II data suggest mezagitamab has the potential to become an innovative new treatment option for these highly refractory ITP patients.”
Obi Umeh, Vice President, Franchise Global Program Leader at Takeda, added: “These results further underscore Takeda’s goal to develop transformative treatments in therapeutic areas with high unmet patient needs. We look forward to seeing further outcomes from mezagitamab in ITP as part of our ongoing Phase III trial.”
